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Abstract
Background
Few studies have examined fetal, infant and maternal mortality and morbidity among preg-
nant women at very early gestation with an open cervix and prolapsed membranes. We car-
ried out a study describing the outcomes of women hospitalized with prolapsed membranes
at 22–28 weeks’ gestation.
Methods
We prospectively recruited women with singleton pregnancies admitted at 22–28 weeks’
gestation to tertiary hospitals of the Canadian Perinatal Network between 2005 and 2009.
Time-to-delivery, perinatal death, neonatal intensive care unit (NICU) admission, severe
neonatal morbidity and severe maternal morbidity were compared between women admit-
ted at 22–25 vs. 26–28 weeks gestation. Logistic regression was used to estimate adjusted
odds ratios (AOR) and 95% confidence intervals.
Results
129 women at 22–25 weeks gestation and 65 women at 26–28 weeks gestation were admit-
ted to hospital and the median time-to-delivery was 4 days in both groups. Stillbirth rates
were 12.4% vs 4.6% among women admitted at earlier vs later gestation (AOR 2.8, 95% CI
0.5–14.8), while perinatal death rates were 38.0% vs 6.1% (AOR 14.1, 95% CI 3.5–59.0),
respectively. There were no significant differences in NICU admission and severe morbidity
among live-born infants; 89.4% and 82.3% died or were admitted to NICU, (P value 0.18),
and 53.9% vs 44.0% of NICU infants had severe neonatal morbidity (P value 0.28). Antibiot-
ics, tocolysis and cerclage did not have a significant effect on perinatal death. Maternal
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death or severe maternal morbidity occurred in 8.5% and 6.2% of women admitted at 22–25
vs 26–28 weeks (AOR 1.2, 95% CI 0.4–4.2).
Conclusion
Perinatal mortality among women with prolapsed membranes at very early gestation is high,
although significantly lower among those admitted at a relatively later gestational age.
Rates of adverse maternal outcomes are also high. This information can be used to counsel
women with prolapsed membranes at 22 to 28 weeks gestation.
Introduction
Preterm birth remains a major cause of neonatal morbidity and mortality, with especially high
rates of death and illness at very early gestation. Survival rates are estimated to be approxi-
mately 54% at 25 weeks of gestation, 38% at 24 weeks, and 23% at 23 weeks gestation [1].
Despite advances in neonatal care, the morbidity for infants born between 24 and 26 weeks of
gestation continues to be significant; nearly 50% of infants born before 25 completed weeks
have one or more disability [2].
Studies show that a short cervix is an accurate predictor of preterm birth [3–5]; an open cer-
vix with prolapsed membranes at midtrimester conveys a more serious prognosis. The inci-
dence of short cervix ranges from about 2–6% and the incidence of an open cervix is likely
lower [6–8]. Exposure of membranes to the vaginal flora may predispose to infection or rup-
ture of membranes, and prolapsed membranes presage imminent delivery especially in the
absence of intervention [9–11]. Despite the grave prognosis associated with prolapsed mem-
branes at early gestation, fetal, infant and maternal mortality and morbidity among women
diagnosed with an open cervix with prolapsed membranes have not been adequately studied.
The few small clinical trials that have compared rescue cerclage with expectant management
involved clinically heterogeneous populations; these trials included women with prolapsed
membranes diagnosed at varying gestational ages (some <20 weeks gestation) [12–17].
We carried out a study describing fetal, infant and maternal outcomes among a large cohort
of pregnant women with a diagnosis of prolapsed membranes prior to 29 weeks of gestation.
We compared women with a diagnosis of prolapsed membranes at 22–25 weeks versus 26–28
weeks of gestation in terms of time to delivery, obstetric intervention, maternal morbidity, and
birth outcomes. In addition, we examined the use of antenatal steroids, antibiotics, tocolysis
and cerclage in relation to birth outcomes among these women.
Methods and Materials
We carried out a prospective study of women admitted to hospital with prolapsed membranes
at 22–28 weeks’ gestation between 2005 and 2009 using data collected prospectively by the
Canadian Perinatal Network (CPN). During this period, CPN collected information on all
women admitted at 22+0 to 28+6 weeks gestation for pregnancy complications to participating
tertiary perinatal hospitals and perinatal centers across Canada. Information about maternal
demographic, behavioral and clinical characteristics, pregnancy complications and birth out-
comes was abstracted from hospital charts by trained data abstractors.
Enrolled women were followed up until delivery including during re-hospitalization.
Information on stillbirth, maternal death, maternal morbidity and intensive care unit (ICU)
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admissions was abstracted from maternal hospital charts. While information about live
born infants who did not require neonatal intensive care unit (NICU) admission was
obtained directly from the neonatal hospital records, information on infants admitted to
NICU was obtained though a linkage to the Canadian Neonatal Network (CNN), which col-
lected detailed information on infants admitted to NICUs across Canada. Collected data
included infant death before discharge and neonatal morbidity, e.g., bronchopulmonary
dysplasia (BPD) and severe intraventricular hemorrhage (IVH). In addition, CNN collected
data to calculate the Score for Neonatal Acute Physiology (SNAP-II). This score measures
the severity of the neonatal condition after birth and within the first 24 hours, and includes,
for example, urine output, neonatal blood pressure, neonatal seizures, and oxygen satura-
tion. High SNAP II values indicate higher degree of neonatal morbidity and a high risk for
neonatal death.
Our study included women with singleton pregnancies admitted for, or diagnosed with,
prolapsed membranes during hospitalization at 22–28 weeks gestation. Pregnancies with con-
genital anomalies were excluded. Women with prolapsed membranes were defined as those
with a dilated cervix with membranes at or beyond the external os as visualized on speculum
examination, or those with any cervical dilatation of the external os by endovaginal ultrasound
examination. Women with severe prolapsed membranes were defined as those with a2cm
dilated cervix or ‘hour-glassing’ (i.e., membranes beyond the cervical os).
Maternal outcomes of interest included time to delivery after diagnosis of prolapsed mem-
branes (in days), maternal death and severe maternal morbidity. Severe maternal morbidity
was defined as any of the following potentially life threatening conditions: abruptio placentae,
need for injectable antihypertensives or positive inotropic support, myocardial ischemia/
infarction, blindness, eclampsia, coma (Glasgow score<13), stroke, other adverse neurological
events, disseminated intravascular coagulation, hysterectomy, embolization, sepsis, endome-
tritis, intubation, non-invasive ventilation, pulmonary edema, oxygen requirement for >1
hour (>50% O2), acute renal failure, dialysis, hepatic failure/dysfunction, hepatic hematoma/
rupture, and thromboembolism. Admission to an intensive care unit (ICU) or high depen-
dency obstetrical unit and chorioamnionitis (suspected or confirmed) were also studied.
Fetal/neonatal outcomes of interest included fetal death, neonatal death before discharge,
admission to the neonatal intensive care unit (NICU), and severe neonatal morbidity (for
NICU infants only) defined as any of the following: BPD defined as need for supplemental
oxygen or respiratory support at 36 weeks postmenstrual age, IVH grade 3 and 4, retinopathy
of prematurity (ROP, stage 3 or higher), necrotizing enterocolitis (NEC), neonatal sepsis, neo-
natal seizures, and central nervous system shunt placement.
The study population was categorized into two subcohorts, women who were diagnosed
with prolapsed membranes at 22–25 weeks and 26–28 weeks gestation. The statistical signifi-
cance of differences in maternal and clinical characteristics between the groups was assessed
using a chi-square or Fisher’s exact test, while differences in the time to delivery between the
groups were assessed using a log-rank test. Maternal and birth outcomes were compared using
logistic regression to adjust for potential confounders. For maternal outcomes, the confound-
ers included in the logistic model were maternal age, marital status, gravidity, smoking during
pregnancy, and alcohol and drug use. For birth outcomes, adjustment was also made for previ-
ous stillbirth, previous preterm birth<37 weeks, and use of cerclage, antenatal corticosteroids,
antibiotics, or tocolysis. In the primary analysis we did not adjust for choriamnionitis, short
cervix, antepartum hemorrhage, placental abruption, and preterm labour since these variables
could be in the pathway between prolapsed membranes and perinatal outcomes. However, in
secondary analyses of perinatal outcomes we additionally adjusted for these variables in order
to ascertain any (indirect) effects potentially mediated by these variables.
Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation
PLOS ONE | DOI:10.1371/journal.pone.0168285 December 21, 2016 3 / 13
Analyses were also carried out to assess the potential effects of cerclage, antepartum antibi-
otics, antenatal corticosteroids, and tocolysis on live birth34 weeks, NICU admission, still-
birth and perinatal death. Interaction terms were added to the logistic regression model to
assess whether the efficacy of these treatments was different among women with prolapsed
membranes at 22–25 weeks vs 26–28 weeks gestation.
All analyses were carried out using SAS software, version 9.3 (SAS Institute Inc., Cary NC).
The Research Ethics Committee at each participating centre reviewed and approved the CPN
protocol as a quality assurance project and waived the requirement for individual informed
consent. The names of the participating centres, the Research Ethics Committee and the ethics
approval certificate number are as follows: Victoria General Hospital, Victoria, BC, Island
Health Research Ethics Board, Certificate No. H2007-68; British Columbia Women’s Hospital
and Health Centre, Vancouver, BC, University of British Columbia Research Ethics Board,
Certificate No. H05-70359; Foothills Medical Centre, Calgary, AB, Conjoint Health Research
Ethics Board, Certificate No. E-21281; Royal Alexandra Hospital, Edmonton, AB, Health
Research Ethics Board, Certificate No. Pro00001472_REN3; Royal University Hospital, Saska-
toon, SA, University of Saskatchewan Research Ethics Board, Certificate No. Bio 06–04; Regina
General Hospital, Regina, SA, Ethics Committee, Regina Qu’Appelle Health Region, Certifi-
cate No. REB-06-33; Kingston General Hospital, Kingston, ON, Queen’s University Health
Sciences & Affiliated Teaching Hospital Research Ethics Board, Certificate No. OBGY-153-06;
McMaster University Medical Centre, Hamilton, ON, McMaster Research Ethics Board, Cer-
tificate No. 09–452; London Health Sciences Centre, London, ON, Health Sciences Research
Ethics Board—Western University, Certificate No. 5677; Mount Sinai Hospital, Toronto, ON,
Mount Sinai Hospital Research Ethics Board, Certificate No. 06-0019-C; The Ottawa Hospital,
Ottawa, ON, Ottawa Health Science Network Research Ethics Board, Certificate No. 2006145-
01H; Universitaire de Sherbrooke, Sherbrooke, QU, CHUS Human Research Ethics Commit-
tee, Certificate No. 06–128; Centre Hoˆspitalier de L’Universite´ Laval, Quebec City, QU,
Comite´ d’e´thique de la recherche´, Certificate No. 95.05.10; Centre Hoˆspitalier Universitaire
Sainte-Justine, Montreal, QU, Research Ethics Board of the Sainte-Justine University Hospital,
Certificate No. 2275; IWK Health Centre, Halifax, NS, IWK Health Centre Research Ethics
Board, Certificate No. 1004849; and the Women’s Health Program, Eastern Health, St. John’s,
NFL, Health Research Ethics Authority, Certificate No. 06.51.
Results
The study population consisted of 194 pregnant women with singleton non-anomalous fetuses
who were diagnosed with or admitted to tertiary care hospitals or perinatal centers in Canada
for prolapsed membranes at 22–28 week gestation between 2005 and 2009. 129 women had a
diagnosis of prolapsed membranes between 22 and 25 weeks, while 65 women were diagnosed
between 26 and 28 weeks gestation. Women in the latter group were more likely to be unmar-
ried (18.5% vs 8.5%, Table 1), but did not differ significantly with regard to primigravidity,
obstetric history, smoking in pregnancy and other factors.
Although those diagnosed at earlier gestation tended to deliver at earlier gestation, the
median number of days to delivery was 4 days in both cohorts. Approximately 25% vs 32% of
women delivered within one day after diagnosis in the 22–25 weeks vs 26–28 weeks cohorts
respectively, while 32% vs 29% delivered more than 10 days after diagnosis (Table 1). The
duration between diagnosis and delivery did not differ significantly between the groups (Fig
1). Among women with prolapsed membranes diagnosed at 26–28 weeks, all stillbirths
occurred within the first 2 days after diagnosis (3 stillbirths), while among women with an
Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation
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Table 1. Characteristics of women with prolapsed membranes at 22–25 weeks vs 26–28 weeks gestation (singleton pregnancies without congeni-
tal anomalies).
Demographic and clinical factors Prolapsed membranes P-value
22–25 weeks 26–28 weeks
N = 129 (%) N = 65 (%)
Maternal age (years) <20 5 (3.9) 4 (6.1) 0.38
20–24 27 (20.9) 11 (16.9)
25–29 42(32.6) 17 (26.1)
30–34 30 (23.3) 23 (35.4)
35–39 18 (13.9) 9 (13.8)
40 7 (5.4) 1 (1.5)
Unmarried 11 (8.5) 12 (18.5) 0.04
Primigravida 42 (32.6) 25 (38.5) 0.41
Multipara 58 (45.0) 27 (41.5) 0.93
Prior stillbirth 7 (5.4) 2 (3.1) 0.72
Prior birth <34 weeks 19 (14.7) 6 (9.2) 0.28
Prior birth <37 weeks 27 (20.9) 11 (16.9) 0.51
Smoking during pregnancy 31 (24.4) 19 (29.7) 0.43
Alcohol 13 (10.2) 3 (4.8) 0.27
Drugs 4 (3.2) 6 (9.4) 0.09
Male fetus/infant 65 (50.4) 27 (41.5) 0.24
Gestational age at diagnosis: No. (%) <0.001
22 weeks 16 (12.4) -
23 weeks 38 (29.5) -
24 weeks 46 (35.7) -
25 weeks 29 (22.5) -
26 weeks - 24 (36.9)
27 weeks - 18 (27.7)
28 weeks - 23 (35.4)
Time-to-delivery (days)*
Median (IQR) 4 (17) 4 (13) 0.47
No. (%) 0 days 13 (10.1) 13 (20.0) 0.40
1 day 19 (14.7) 8 (12.3)
2 days 13 (10.1) 5 (7.7)
3–5 days 32 (24.8) 12(18.4) (18.5)
6–10 days 11 (8.5) 8 (12.3)
>10 days 41 (31.8) 19 (29.2)
Gestational age at delivery (weeks)
Median (IQR) 25 (2) 28 (2) <0.001
No. (%) 22–25 weeks 94 (72.9) 0 (0) <0.001
26–28 weeks 17 (13.2) 46 (70.8)
29–33 weeks 6 (4.6) 9 (13.8)
34–36 weeks 4 (3.1) 5 (7.7)
37–43 weeks 8 (6.2) 5 (7.7)
* Number of days between diagnosis of prolapsed membranes and delivery.
Note: There were 3 missing values for smoking during pregnancy, and 4 missing values for alcohol and drug use.
doi:10.1371/journal.pone.0168285.t001
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earlier diagnosis, the majority of stillbirths occurred after 2 days following diagnosis of pro-
lapsed membranes (11 out of 16 stillbirths).
There were no significant differences in pregnancy complications between women diag-
nosed at 22–25 weeks vs 26–28 weeks, with both groups having similar rates of preterm prela-
bour rupture of membranes, preterm labour, short cervix, antepartum hemorrhage, placenta
accreta, placental abruption, gestational diabetes, hypertension in pregnancy, and cesarean
delivery (Table 2). The rates of chorioamnionitis were also similar (9.3% vs 10.8%, respec-
tively). However, women with an earlier diagnosis of prolapsed membranes were significantly
more likely to receive antibiotics (73.6% vs 58.5%), and cerclage (23.3% vs 4.6%), but less likely
to receive antenatal corticosteroids (72.9% vs 86.5%) compared with women diagnosed at 26–
28 weeks (Table 2).
Women in both groups had relatively high rates of maternal morbidity, and no significant
differences between groups were observed. There was 1 maternal death among women with
prolapsed membranes at 22–25 weeks, and 8.5% vs 6.2% of women with prolapsed membranes
at 22–25 vs 26–28 weeks gestation experienced death or maternal morbidity (Table 3).
The perinatal mortality rate was significantly higher among women with prolapsed mem-
branes diagnosed at 22–25 vs 26–28 weeks (38.0 vs 6.1 per 100 total births; odds ratio 9.3, 95%
CI 3.2–27.3; Table 4). The strength of this association was essentially unchanged after adjust-
ment for maternal characteristics and treatments received (adjusted odds ratio AOR 9.1, 95%
CI 2.5–33.5). Adjustment for variables potentially in the causal pathway (chorioamnionitis,
short cervix, etc) increased the strength of the association and also the width of the 95% confi-
dence intervals (AOR 14.1, 95% CI 3.5–59.0). Stillbirth rates were higher among women with
early vs later diagnosis, but these differences were not statistically significant (12.4 vs 4.6 per
Fig 1. Proportion of undelivered pregnancies after a diagnosis of prolapsed membranes at 22–25 vs 26–28 weeks’
gestation among women with non-anomalous singleton pregnancies.
doi:10.1371/journal.pone.0168285.g001
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100 total births, P value 0.12). The majority of stillbirths occurred intra-partum (87% and 67%
in each group). A lower proportion of live born infants was admitted to NICU among women
with prolapsed membranes at 22–25 vs 26–28 weeks (68.1% vs 82.3%, P value 0.04). However,
the rates of delivery34 weeks were similar in the 2 groups, while rates of death before hospi-
tal discharge were significantly higher among women with prolapsed membranes at 22–25
weeks (Table 4).
NICU infants born to mothers diagnosed at 22–25 weeks gestation had a higher SNAP-II
score and a higher number of days on ventilation (S1 Table). A larger proportion of the NICU
infants of mothers with prolapsed membranes at 22–25 weeks stayed in the NICU for more
than 90 days as compared with NICU infants born to mothers with prolapsed membranes at
26–28 weeks gestation (31.6% vs 8.0%, P value 0.002). However, the combined outcome of
death or severe neonatal morbidity was not significantly different between NICU infants born
to mothers diagnosed at 22–25 vs 26–28 weeks (59.2% vs 44.0%, respectively, P value 0.09).
Treatment with antibiotics, tocolysis and cerclage did not have a significant effect on
perinatal death (Table 5). However, antenatal corticosteroid use was associated with a
Table 2. Pregnancy complications, labour characteristics and interventions among women with prolapsed membranes at 22–25 vs 26–28 weeks
gestation (singleton pregnancies without congenital anomalies).
Pregnancy complications/interventions Prolapsed membranes P-value
22–25 weeks 26–28 weeks
N = 129 (%) N = 65 (%)
Complications
Severe prolapse of membranes 96 (74.4) 42 (64.6) 0.16
PPROM 21 (16.3) 9 (13.8) 0.66
Preterm labour 34 (26.4) 19 (29.2) 0.67
Short cervix 27 (20.9) 15 (23.1) 0.73
Antepartum hemorrhage 34 (26.4) 13 (20.0) 0.33
Placenta accreta 0 (0.0) 1 (1.5) 1.00
Abruptio placentae 9 (7.0) 2 (3.1) 0.27
Chorioamnionitis 12 (9.3) 7 (10.8) 0.75
Sepsis 2 (1.6) 0 (0.0) 0.55
Gestational diabetes 1 (0.8) 1 (1.5) 1.00
Hypertension in pregnancy 1 (0.8) 1 (1.5) 1.00
Labour and intervention
Spontaneous labour 97 (75.2) 49 (75.4) 0.98
Induction of labour 14 (10.8) 5 (7.7) 0.48
Augmentation of labour 8 (6.2) 4 (6.1) 1.00
Cesarean delivery 36 (27.9) 24 (36.9) 0.20
Emergency* 31 (86.1) 23 (95.8) 0.22
Vaginal delivery 93 (72.1) 41 (63.8)
Assisted* 10 (10.7) 3 (7.3) 0.75
Antenatal steroids 94 (72.9) 56 (86.5) 0.04
Antibiotics (antepartum) 95 (73.6) 38 (58.5) 0.03
Tocolysis 63 (48.8) 28 (43.1) 0.45
Cerclage 30 (23.3) 3 (4.6) 0.001
PPROM denotes preterm prelabour rupture of membranes.
* Emergency cesarean rate calculated among women with cesarean deliveries and assisted vaginal delivery rates calculated among women with vaginal
deliveries.
doi:10.1371/journal.pone.0168285.t002
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lower risk of stillbirth (AOR 0.14, 95% CI 0.02–0.98) and perinatal death (AOR 0.21, 95% CI
0.06–0.70). Interaction terms showed that the observed effects of these interventions were
not significantly different between women with prolapsed membranes at 22–25 weeks vs
women with prolapsed membranes at 26–28 weeks gestation except for the association
between antepartum antibiotics and live birth 34 weeks. Antepartum antibiotics were
non-significantly positively associated with live birth 34 weeks among women with pro-
lapsed membranes at 22–25 weeks (AOR 4.41, P value 0.25), while a significant negative
association was found among women with prolapsed membranes at 26–28 weeks (AOR
0.01, P value 0.01).
Table 3. Maternal death and severe maternal morbidity rates among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (single-
ton pregnancies without congenital anomalies).
Maternal death/morbidity Prolapsed membranes P-value Odds ratio Adjusted odds ratio
22–25 weeks 26–28 weeks (95% CI) (95% CI)
N = 129 (%) N = 65 (%) (22–25 vs 26–28 wks) (22–25 vs 26–28 wks)
Maternal death 1 (0.78) 0 (0.00) 1.00 - -
Intensive Care Unit admission 3 (2.33) 3 (4.62) 0.40 0.49 (0.10–2.51) 0.51 (0.10–2.65)
Blood transfusion/blood products 3 (2.33) 0 (0.00) 0.55 - -
Severe maternal morbidity* 8 (6.20) 2 (3.08) 0.50 2.08 (0.43–10.1) 2.17 (0.41–11.47)
Maternal death/morbidity† 11 (8.53) 4 (6.15) 0.78 1.42 (0.43–4.65) 1.23 (0.36–4.19)
Adjusted odds ratio adjusted for maternal age, marital status, gravidity, smoking during pregnancy, alcohol and drug use.
* Severe maternal morbidity included abruptio placentae, need for injectable antihypertensives, positive inotropic support, myocardial ischemia/infarction,
blindness, eclampsia, coma (Glasgow score<13), stroke, adverse neurological events, disseminated intravascular coagulation, hysterectomy, embolization,
sepsis, endometritis, intubation, non-invasive ventilation, pulmonary edema, oxygen requirement for >1 h (>50% O2), acute renal failure, dialysis, hepatic
failure/dysfunction, hepatic hematoma/rupture, and thromboembolism.
† Maternal death/morbidity included maternal death, severe maternal morbidity, blood transfusion/blood products, or Intensive Care Unit admission.
doi:10.1371/journal.pone.0168285.t003
Table 4. Perinatal outcomes among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (singleton pregnancies without con-
genital anomalies).
Perinatal outcomes Prolapsed membranes P-value Odds ratio Adjusted odds Adjusted odds
(95% CI) ratio1 (95% CI) ratio2 (95% CI)22–25 weeks 26–28 weeks
N = 129 (%) N = 65 (%)
Perinatal death*† 49 (38.0) 4 (6.1) <0.001 9.34 (3.20–27.3) 9.08 (2.46–33.5) 14.1 (3.50–59.0)
Stillbirth 16 (12.4) 3 (4.6) 0.12 2.93 (0.82–10.4) 2.08 (0.44–9.78) 2.77 (0.52–14.8)
Live birth N = 113 N = 62
Gestational age at delivery >33 weeks‡ 12 (10.6) 10 (16.1) 0.29 0.62 (0.25–1.53) 0.74 (0.22–2.46) 0.72 (0.23–2.30)
Death before discharge* 33 (29.5) 1 (1.6) <0.001 25.1 (3.33–188.4) 22.9 (2.69–194.8) 25.5 (3.00–217.1)
NICU admission 77 (68.1) 51 (82.3) 0.04 0.46 (0.22–0.99) 0.38 (0.15–0.96) 0.40 (0.15–1.06)
Death before discharge/NICU admission 101 (89.4) 51 (82.3) 0.18 1.82 (0.75–4.40) 1.63 (0.57–4.67) 1.69 (0.53–5.39)
* One infant in each group had missing data on NICU follow-up.
† Includes stillbirth or death before hospital discharge.
‡ No perinatal death occurred after 33 weeks gestation.
Adjusted odds ratio1: Adjusted for maternal age, marital status, gravidity, smoking during pregnancy, alcohol and drug use, previous stillbirth, previous
preterm birth less than 37 weeks, and use of antepartum antibiotics, cerclage, tocolysis and steroid.
Adjusted odds ratio2: Additionally adjusted for choriamnionitis, short cervix, antepartum hemorrhage, placental abruption, and preterm labour.
doi:10.1371/journal.pone.0168285.t004
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Discussion
Our study showed that the likelihood of a pregnancy continuing for any significant duration
following a diagnosis of prolapsed membranes was low with a median duration of pregnancy
after the diagnosis of prolapsed membranes of 4 days. Women with prolapsed membranes had
a relatively high rate of other pregnancy complications, such as preterm prelabour rupture of
membranes, preterm labour, antepartum hemorrhage, chorioamnionitis and placental abrup-
tion. Similarly, women with prolapsed membranes had a high rate of severe maternal morbid-
ity, regardless of gestational age at diagnosis. Perinatal mortality rates were higher among
women diagnosed with prolapsed membranes at 22–25 weeks compared with women diag-
nosed at 26–28 weeks gestation due to a higher stillbirth rate and higher rates of infant death
before discharge.
A few previous studies on women with prolapsed membranes have reported a 2 to 3 week
latency between the diagnosis of prolapsed membranes and delivery [12–17]. These studies
compared women who received emergency cerclage, and women who had bed rest or were
managed without intervention. The studies were typically small, although one study included
161 women between 17 and 26 weeks gestation and reported a median time-to-delivery inter-
val of 3 days [16].
Perinatal mortality rates in our study were high, especially among mothers with prolapsed
membranes diagnosed at 22–25 weeks gestation (38.0%); these high rates are consistent with
the findings from previous studies [13–16]. Severe maternal morbidity rates among women
with prolapsed membranes at 22 to 28 weeks gestation were also high; 8.5% of those diagnosed
at 22–25 weeks and 6.2% of those diagnosed at 26–28 weeks experienced maternal death or
severe morbidity. Few previous studies have examined maternal morbidity related to a diagno-
sis of prolapsed membranes in early gestation and these were restricted to reports of sepsis and
chorioamnionitis [12,13,17].
The results of our study are important for counseling patients. The probability of neonatal
survival without major morbidity is low when a diagnosis of prolapsed membranes is made at
22–25 weeks. Expectant management in this situation may be an option, but is associated with
poor fetal and neonatal outcomes and significant maternal risk. Conversely, when a diagnosis
of prolapsed membranes is made at 26–28 weeks of gestation, perinatal mortality rates are
Table 5. Adjusted odds ratios expressing the association between antibiotics, antenatal steroids, cerclage and tocolysis on perinatal outcomes
among women with prolapsed membranes 22–28 weeks gestation (singleton pregnancies without congenital anomalies).
Birth outcome Adjusted odds ratios* (95% CI) for effects of
Antibiotics Antenatal steroids Cerclage Tocolysis
Perinatal death† 1.54 (0.49–4.87) 0.21 (0.06–0.70) 0.21 (0.05–0.85) 0.75 (0.28–2.03)
Stillbirth 1.15 (0.17–7.75) 0.14 (0.02–0.98) 1.23 (0.15–10.07) 1.58 (0.26–9.77)
Death before discharge 2.52 (0.48–13.36) 0.27 (0.05–1.46) 0.17 (0.02–1.18) 0.75 (0.18–3.10)
Death before discharge or NICU admission 1.52 (0.50–4.57) 0.13 (0.01–1.30) 0.68 (0.19–2.48) 1.22 (0.45–3.30)
Delivery >33 weeks 5.94 (0.52–16.8) 3.08 (0.56–16.84) 1.00 (0.23–4.28)
Prolapsed membranes at 22–25 weeks 4.41 (0.36–54.7)
Prolapsed membranes at 26–28 weeks 0.01 (0.00–0.40)
* Adjusted for gestational age at the diagnosis of prolapsed membranes, maternal age, marital status, gravidity, smoking during pregnancy, alcohol and
drug use, previous stillbirth, previous preterm birth less than 37 weeks, and other co-interventions included in the Table. Adjusted odds ratio for the
association between antibiotics use and delivery of a live newborn at >33 weeks differed between women diagnosed with prolapsed membranes at 22–25
and 26–28 weeks gestation.
† Includes stillbirth or death before hospital discharge.
doi:10.1371/journal.pone.0168285.t005
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relatively lower; therefore, patients can be reassured that expectant management (without
cerclage) is a reasonable option and results in relatively low rates of neonatal morbidity and
mortality.
In our study, tocolysis or cerclage did not appear to offer any benefit to women with pro-
lapsed membranes at 22 and 28 weeks. However, the non-experimental nature of our study
precludes strong inferences because of the potential for confounding by indication [18]. On
the other hand, significant ‘protective’ associations were observed between antenatal cortico-
steroids use and stillbirth and perinatal death. In addition, antepartum antibiotics appeared to
have a different effect in prolonging gestation for women at 22–25 weeks vs women at 26–28
weeks at diagnosis of prolapsed membranes; antibiotics were protective among women at 22–
25 weeks and a risk factor at 26–28 weeks. These associations, however, were possibly biased
by reverse causality and confounded by indication; e.g., women with a stillbirth or at imminent
risk of stillbirth were likely not offered antenatal corticosteroid prophylaxis and antibiotics
may have been preferentially given to women with signs of infection especially at 26–28 week.
The strengths of our study include its relatively large size, the inclusion of data from multi-
ple tertiary centres in Canada, and the reporting of both neonatal and maternal outcomes. Our
results were unaffected by differences in medical insurance availability, as all Canadian resi-
dents are covered by universal health care insurance. Our study has a few limitations. First, we
did not have information on the intention to continue pregnancy among women with pro-
lapsed membranes at 22–25 weeks. It is possible that some women did not wish to continue
pregnancy given the anticipated complications. Second, we did not know the exact timing of
cerclage. In some cases, cerclage may have been placed and possibly removed prior to diagno-
sis of prolapsed membranes. Finally, we did not provide comparisons with pregnancy out-
comes among women without prolapsed membranes, who mostly deliver at term gestation
and have much lower rates of adverse maternal and neonatal outcomes.
Conclusion
In conclusion, the results of this relatively large, multicentre study shows that diagnosis of pro-
lapsed membranes between 22–25 weeks carries a high risk of perinatal morbidity and mortal-
ity. Relatively high rates of maternal morbidity are also to be expected in this population.
Among women with prolapsed membranes at 26–28 weeks, neonatal morbidity and mortality
are much lower, though maternal morbidity remains significant. Regardless of gestational age
at diagnosis, fifty percent of women with prolapsed membranes at 22–28 weeks deliver within
4 days and only 10–15% of these women will deliver at 34 weeks of gestation or later. The prog-
nostic information in our study, which shows differences in perinatal outcomes by gestational
age at diagnosis of prolapsed membranes, will be useful for counseling pregnant women with
prolapsed membranes at early gestation.
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